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Abstract
Background: The objective of our study was to evaluate the clinical significance of invisible prostate cancer (iPCa)
on multiparametric magnetic resonance imaging (mpMRI) by analyzing clinical parameters and oncologic
outcomes.
Methods: We retrospectively reviewed the records of patients treated with radical prostatectomy (RP) from 2010 to
2015 at our institution. Before RP, all patients were confirmed to have prostate cancer based on prostate biopsy. We
excluded patients who underwent neoadjuvant therapy. Additionally, we excluded patients who had incomplete
mpMRI based on PI-RADS (Prostate Imaging Reporting and Data System). iPCa was defined as having no grade 3 or
higher region of interests using a scoring system established by PI-RADS without limitations on interpretation from
mpMRI by radiologists. We selected patients with iPCa using this protocol. We analyzed data using univariate and
multivariate cox regression analysis, logistic analysis, Kaplan-Meier curves, and receiver operator characteristic curves
to predict biochemical recurrence (BCR).
Results: A total of 213 patients with iPCa were selected according to the patient selection protocol. Among them,
pathological findings showed that Gleason score (GS) G6, G7 and ≥ G8 were present in 115 cases (54.0%), 78 cases
(36.6%), and 20 cases (9.4%), respectively. Further, extracapsular extension (ECE), positive surgical margins (PSM), and
lymphovascular invasion (LVI) were present in 28 (13.1%), 18 (8.5%), and 3 cases (1.4%), respectively. Seminal vesicle
invasion (SVI) was observed in one case (0.5%). During a median follow-up time of 51 months, BCR was observed
29 cases. Adverse pathology (AP) was defined as GS ≥8, ECE, SVI and LVI. AP and prostate specific antigen (PSA)
were significantly associated with BCR. Moreover, PSA > 6.2 ng/ml was suggested as a cut-off value for predicting
BCR.
Conclusions: In our results, cases of iPCa had clinically significant PCa, and AP and poor prognosis were also
observed in some. Additionally, we found that PSA is the most clinically reliable predictor of oncologic outcome.
We suggest that active treatment and diagnosis should be considered for patients with iPCa with PSA > 6.2 ng/ml.
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Background
Prostate cancer (PCa) is the most common type of newly
diagnosed malignancy in males [1], and it accounts for
nearly 30% of all diagnosed male cancers [2]. In 2012,
around 1,111,700 new cases and 307,500 deaths were re-
corded worldwide [3]. As PCa screening by measuring
prostate-specific antigen (PSA) levels has become more
widespread, the proportion of PCa presenting with
low-risk factors has also increased. [4] According to the
European Association of Urology guidelines, an extended
12-core systematic transrectal ultrasound (TRUS)-guided
biopsy should be performed for patients with an elevated
prostate specific antigen (PSA) level, which is endorsed as
the optimal biopsy method [5]. However, this diagnostic
strategy has disadvantages based on random sampling and
is largely operator dependent. [6]
Accordingly, several complementary measures are being
developed. Since its first usage in 1983, magnetic reson-
ance imaging (MRI) has increasingly been used for PCa
diagnosis because of its growing availability, multipara-
metric imaging, and the combination of anatomic and
functional data [7]. The accuracy of multiparametric mag-
netic resonance imaging (mpMRI) has not only been
established for biopsy specimens, but also for histopatho-
logic correlations using prostatectomy specimens. Recent
publications have demonstrated detection rates of signifi-
cant PCa between 80 and 96% for MRI compared to
whole-mount sections [8–10] Therefore, imaging tech-
niques have played an increasingly important role in the
management of localized PCa. Moreover, mpMRI-TRUS
fusion-targeted biopsy represents a substantial step for-
ward in the detection of PCa. [11] Therefore, the clinical
significance of invisible PCa on mpMRI tends to be
overlooked.
However, despite advances in imaging and target bi-
opsy, mpMRI still produces some false negatives and
false positives [12–14], and not all PCa is detected by
mpMRI. Therefore, the aim of our study was to evaluate
the clinical significance of invisible prostate cancer
(iPCa) on mpMRI. We examined clinical and patho-
logical characteristics to evaluate oncology outcomes fol-
lowing radical prostatectomy (RP) in patients with iPCa.
Methods
Study design and patients
We retrospectively retrieved the clinical and pathological
data of 3057 individuals with PCa who underwent
mpMRI before RP at our institution between January
2010 and December 2015. Among them, patients who
had undergone androgen deprivation therapy (ADT), or
radiation therapy (RT) before the RP were excluded
from the study. Before RP, all patients were diagnosed
with PCa through a TRUS-guided 12-core systematic
needle biopsy.
Additionally, we reviewed only patients with mpMRI
based on the Prostate Imaging Reporting and Data Sys-
tem (PI-RADS) [15, 16], including standardized criteria
for Likert scoring of multiparametric sequences (T1-
weighted [T1W] and T2-weighted [T2W] imaging,
diffusion-weighted imaging [DWI], apparent-diffusion
coefficient [ADC] and dynamic contrast enhanced im-
aging [DCE]) using a 3.0 T MRI system (Intera Achieva
3.0 T, Phillips Medical System, Best, The Netherlands).
All images were retrospectively reviewed by three expe-
rienced uroradiologists who were blinded to biopsy re-
sults and who conducted a consensus review of the
mpMRI images of all patients. In mpMRI, suspicious le-
sions were graded 1–5 using a scoring system estab-
lished by PI-RADS. Negative MRI findings were defined
as having no grade 3 or higher region of interests with-
out limitations on interpretation from mpMRI by radiol-
ogists. We defined this as an iPCa [8, 12].
Of 3057 patients, 642 (640 ADT, 2 RT) (642/3057,
21.0%) had neoadjuvant therapy. Of the remaining 2415
patients, 520 (520/2415, 21.53%) underwent incomplete
mpMRI based on PI-RADS. The remaining 1895 patients
underwent image review by radiologists, of whom 242 pa-
tients (242/1895, 12.8%) had negative findings on mpMRI.
Of these, 29 patients who had limited image interpretation
due to hemorrhage were excluded. As a result, a total of
213 patients who had an invisible tumor on mpMRI of
clinical stage T1c were enrolled in our study. (Fig. 1).
Clinical characteristics of these patients including age,
body mass index (BMI), accompanying medical history
(hypertension, diabetes mellitus), preoperative PSA, pros-
tate volume measured by TRUS, Gleason score (GS) fol-
lowing prostate biopsy, and pathologic characteristics of
specimens following RP were obtained through a review
of medical records at our institution. All pathologic diag-
nosis was performed by expert pathologists. Biopsy speci-
mens obtained from outside of our hospital were reviewed
by our pathologists. Moreover, the pathologists reviewed
the deficiencies of the pathological report of 213 patients
included in our study and confirmed that there was no
problem. Adverse pathology (AP) was defined as GS ≥8,
extracapsular extension (ECE), seminal vesicle invasion
(SVI), and lymphovascular invasion (LVI) [17–19].
Finally, the TNM stage was determined according to
the 8th edition of the American Joint Committee on
Cancer TNM staging system.
Follow-up
Postoperative PSA follow-up was performed monthly for
the first 6 months, every 3 months for the second year, and
every 6 months thereafter. Biochemical recurrence (BCR)
was defined as any two consecutive increases in serum PSA
≥0.2 ng/ml following RP [20]. BCR-free survival was de-
fined as the time from RP to BCR. The follow-up period
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was calculated from the time of RP to the date of the last
known contact with the patient.
Statistical analysis
Univariate and multivariate Cox proportional hazards re-
gression analyses were performed to assess the associ-
ation between baseline parameters and BCR-free
survival. In addition, univariate and multivariate logistic
regression were carried out for the significant factors of
AP, and the Kaplan-Meier method with log-rank tests
were performed to estimate and compare oncologic out-
comes according to AP and PSA.
Receiver operator characteristic (ROC) curve analysis
was performed to determine optimal cut-off value via
the area under the curve (AUC). A total AUC score of
0.8–0.9 was interpreted as an excellent level and 0.7–0.8
as a good level.
Significant variables from univariate analysis were in-
cluded in the multivariate analysis. Comparisons with p
< 0.05 were considered statistically significant. All statis-
tical analyses were performed using SPSS Statistics soft-
ware, version 23.0 (IBM, Armonk, NY, USA).
Results
Patient and disease characteristics
A total of 213 patients with iPCa were included, and
their baseline clinical and pathological features are
shown in Table 1.
Fig. 1 Flow chart of patient selection
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The median age of patients was 64 years (interquartile
range [IQR] 59–69). The median prostate volume, as
measured by TRUS, was 31.2 ml (IQR 23.2–41.2), and
the median PSA level was 5.35 ng/ml (IQR 4.0–7.5). The
median follow-up from RP was 51 months (IQR 32–70).
Among the patients, 92 had hypertension (43.2%) and
27 had diabetes mellitus (12.7%). Among the biopsy
specimens, 162 had GS 6 (76.1%), 37 had GS 7 (17.4%),
and 14 had GS ≥8 (6.6%).
In specimens following RP, 115 cases were GS 6 (54.0%)
and 78 were GS 7 (36.6%). Furthermore, GS above 8 was
reported in 20 cases (9.4%). Pathologic ≤T2 and ≥T3 were
reported 185 cases (86.9%) and 28 cases (13.1%), respect-
ively. The median tumor volume of specimens following
RP was 0.6 ml (IQR 0.2–1.4). ECE was present in 28 cases
(13.1%), and surgical margins were involved in 18 cases
(8.5%). SVI was observed in one case (0.5%). Perineural in-
vasion was reported in 63 cases (29.6%) and LVI was
present in 3 cases (1.4%). Lymph node metastasis was not
reported. Furthermore, there were no cancer-specific
deaths during the observation period.
Oncologic outcomes and prognostic factors
During the follow up period, we observed 29 cases
(13.6%) with BCR in this study. Univariate and multi-
variate Cox regression analyses were performed with
each clinical parameter for BCR. In these analyses, pre-
operative PSA (hazard ratio [HR] 1.164, p < 0.001), GS
≥8 (HR 5.009, p = 0.004), pathologic T stage (HR 3.621,
p = 0.003), and LVI (HR 5.129, p = 0.039) were all inde-
pendent prognostic factors for BCR. (Table 2).
AP (GS ≥ 8, LVI, ECE and SVI) and PSA were related to
oncologic outcomes. In addition, 43 cases (20.2%) had sta-
tistically significant AP. We analyzed preoperative clinical
parameters to predict AP associated with oncologic prog-
nosis using univariate and multivariate logistic regression
analyses, and found that preoperative PSA (odds ratio [OR]
1.270, p < 0.001), biopsy GS (GS 7 vs. GS 6: OR 4.353, p =
0.001; and GS ≥8 vs. GS 6: OR 28.076, p < 0.001) were inde-
pendent prognostic factors for AP (Table 3). Additionally,
Kaplan-Meier curves showed that BCR-free survival was
significantly decreased in the AP group (log-rank test, p <
0.001). (Fig. 2).
ROC curve and cut-off value of PSA in relation to BCR
Preoperative PSA showed a significant correlation with
the presence of BCR and AP. ROC curve analysis was
used to determine optimal cut-off value by the Youden
Index, as shown in Fig. 2. The optimal cut-off value for
PSA level that can predict BCR was determined to be
6.2 ng/ml, with an AUC of 0.799 (95% confidence inter-
val, 0.721–0.877). This was statistically close to an excel-
lent level. (Fig. 3) We then divided patients into two
groups using the PSA cut-off value. Kaplan-Meier curves
showed a significant difference between the two groups
with respect to BCR (log-rank test, p < 0.001). (Fig. 4).
Discussion
The widespread use of PSA testing has dramatically in-
creased the number of low-risk PCa cases identified. Con-
sequently, the proportion of low-risk PCa cases has
increased, and treatment options for PCa are known to
differ by risk classification [4]. However, several published
Table 1 Baseline patient characteristics
Median IQR
Age, year 64 59–69
BMI, kg/m2 24.5 22.4–26.1
Comorbidity N %
Hypertension 92 43.2
DM 27 12.7
PSA level, ng/ml 5.35 4.0–7.5
Prostate volume, ml 31.2 23.2–41.2
Follow up period after RP, months 51 32–70
Tumor volume at specimen, cc 0.6 0.2–1.4
Biopsy Gleason score N %
6 162 76.1
7 37 17.4
≥ 8 14 6.6
Pathologic Gleason score N %
6 115 54
7 78 36.6
≥ 8 20 9.4
Pathologic T stage N %
≤ T2 185 86.9
≥ T3 28 13.1
ECE N %
28 13.1
SVI N %
1 0.5
PSM(R1) N %
18 8.5
LVI N %
3 1.4
PNI N %
63 29.6
BCR N %
29 13.6
IQR Interquartile range, BMI Body mass index, DM Diabetes mellitus, PSA
Prostate-specific antigen, RP Radical prostatectomy, ECE Extracapsular
extension, SVI Seminal vesicle invasion, PSM Positive surgical margins, LVI
Lymphovascular invasion, PNI Perineural invasion, BCR Biochemical recurrence
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studies have reported that the efficacy of contemporary
PCa screening and diagnosis practices have limited sensi-
tivity and specificity. The main disadvantages are failure to
detect clinically significant cancer, imprecise PCa risk
stratification (undersampling), and detection of small,
low-risk, clinically insignificant cancers (overdetection)
[21, 22]. Thus, the development of mpMRI has played a
role in complementing these deficiencies.
In the past, widespread acceptance of mpMRI suffered
from a lack of standardized diagnostic criteria for report-
ing results, leading to a substantial variability in interpret-
ation [23]. To standardize the evaluation and reporting of
prostate MRI, the European Society of Urogenital Radi-
ology published guidelines based on an expert consensus
in 2012, termed the Prostate Imaging Reporting and Data
System (PI-RADS). This system was then upgraded to
PI-RADS version 2 in 2015. As such, the role of mpMRI
in diagnosing PCa is growing [15, 16].
The standardization of prostate mpMRI and the subse-
quent development of platforms for MRI-targeted biopsy
represent a potential tool to the overcome limitations of
conventional TRUS-biopsy. In addition, this has had a
significant impact on the treatment direction. Notably,
iPCa on mpMRI has been observed in several published
Table 2 Univariate and multivariate analyses of factors associated with biochemical recurrence
Variable Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age, year 1.012 (0.960–1.067) 0.656
PSA, ng/ml 1.198 (1.129–1.272) < 0.001 1.164 (1.069–1.268) < 0.001
BMI, kg/m2 0.943 (0.813–1.093) 0.433
Prostate volume, ml 1.001 (0.981–1.023) 0.892
Hypertension
No 1 (Ref)
Yes 1.548 (0.747–3.210) 0.240
DM
No 1 (Ref)
Yes 0.849 (0.257–2.808) 0.789
Biopsy Gleason score
6 1 (Ref) 1 (Ref)
7 1.952 (0.783–4.866) 0.151 0.957 (0.315–2.913) 0.939
≥ 8 7.052 (2.956–16.828) < 0.001 0.985 (0.179–5.434) 0.986
Pathologic Gleason score
6 1 (Ref) 1 (Ref)
7 2.619 (0.982–6.989) 0.054 1.905 (0.653–5.560) 0.238
≥ 8 13.213 (4.879–35.778) < 0.001 5.009 (1.664–15.076) 0.004
Tumor volume at specimen, cc 1.745 (1.263–2.411) 0.001 0.780 (0.499–1.218) 0.275
Pathologic T stage
≤ T2 1 (Ref) 1 (Ref)
≥ T3 9.721 (4.630–20.411) < 0.001 3.621 (1.535–8.540) 0.003
PSM(R1)
No 1 (Ref) 1 (Ref)
Yes 3.935 (1.778–8.706) 0.001 0.800 (0.271–2.363) 0.686
LVI
No 1 (Ref) 1 (Ref)
Yes 8.455 (1.978–36.133) 0.004 5.129 (1.087–24.187) 0.039
PNI
No 1 (Ref)
Yes 1.677 (0.800–3.514) 0.171
HR Hazard ratio, PSA Prostate-specific antigen, BMI Body mass index, DM Diabetes mellitus, PSM Positive surgical margins, LVI Lymphovascular invasion, PNI
Perineural invasion
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Table 3 Univariate and multivariate analyses of factors associated with adverse pathology
Variable Univariate Multivariate
OR (95% CI) p value OR (95% CI) p value
Age, year 1.032(0.982–1.083) 0.214
PSA, ng/ml 1.291 (1.164–1.430) < 0.001 1.270 (1.141–1.421) < 0.001
BMI, kg/m2 0.972 (0.857–1.103) 0.660
Prostate volume, ml 0.990 (0.965–1.015) 0.418
Hypertension
No 1 (Ref)
Yes 1.683 (0.859–3.299) 0.129
DM
No 1 (Ref)
Yes 1.151 (0.434–3.054) 0.778
Biopsy Gleason score
6 1 (Ref) 1 (Ref)
7 4.870 (2.133–11.118) < 0.001 4.353 (1.770–10.704) 0.001
≥ 8 29.333 (7.473–115.138) < 0.001 28.076 (6.720–117.296) < 0.001
OR Odds ratio, CI Confidence interval, PSA Prostate-specific antigen, BMI Body mass index, DM Diabetes mellitus
Fig. 2 Kaplan-Meier curves for biochemical recurrence (BCR)-free survival in patients according to adverse pathology (GS≥ 8, LVI, ECE and SVI)
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Fig. 3 Receiver operator characteristic curve of PSA levels for predicting the presence of biochemical recurrence
Fig. 4 Kaplan-Meier curves for biochemical recurrence (BCR)-free survival in patients according to prostate-specific antigen levels (PSA, cut-off
value 6.2)
Chung et al. BMC Cancer         (2018) 18:1057 Page 7 of 10
studies, which is considered to be one standard of active
surveillance [24–26].
In addition, some studies have identified mpMRI as an
important prerequisite for prostate biopsy. Wysock et al.
[27] reported that 75 patients had a pre-biopsy MRI show-
ing no suggestion of cancer. In 74 of those patients, no
cancer with GS ≥7 was found by biopsy, which translates
into a remarkable 98.7% negative predictive value for po-
tentially aggressive disease. Thus, they suggested that a
negative MRI result obviates the need for a biopsy.
However, negative findings on MRI have already been
reported in several studies, and MRI-iPCa is also not un-
common in the PI-RADS era. Filson et al. reported that
in a consecutive series of 1042 men undergoing template
biopsy, regardless of MRI findings, the incidence of clin-
ically significant PCa in men with no MRI-suspicious le-
sions was 16%. [12].
Further, in a study by Le et al., when looking carefully
at whole-mount prostatectomy specimens, the incidence
of clinically significant PCa not seen on expert-read MRI
was 28%. [8], which was the same as in our study. A sig-
nificant PCa was observed in some of the pathologic
specimens of 213 patients with iPCa, and then we inves-
tigated their long-term oncologic outcomes. Most cases
of iPCa showed low risk for G6 (76.1%), but PCa of G8
or higher was observed in 20 cases (6.6%), and T3 path-
ology was observed in 24 cases (13.1%). BCR was ob-
served in 29 cases (13.6%) during the follow-up period.
This showed that there may be AP and oncologic out-
comes among invisible cancers.
In addition, 55 patients with iPCa who had a low risk of
G6 in biopsy showed an upgraded feature of G7 or above
in the final pathology. The possibility of upgrading to G6
has already been reported in many articles [19, 28]. We
agree that some GS 6 cases thought to be insignificant
may have the biological potential for de-differentiation.
This suggests that in patients with a low risk of G6, iPCa
on mpMRI finding is not a prerequisite for AS. Our find-
ings will be able to complement this. We found that PSA
is closely related to oncologic outcome and AP. Through
this, we determined the optimal PSA cut-off value to pre-
dict BCR during the follow-up period. PSA > 6.2 ng/ml
could be considered as a basis for determining the active
treatment of iPCa. PSA is still the most reliable marker of
PCa in the era of mpMRI and PI-RADS.
However, our study had several limitations. First, this
was a retrospective review of data from patients treated at
a single institution; therefore, multi-center, prospective
studies are still needed. Second, as we previously men-
tioned, mpMRI scans were obtained after prostate biopsy.
There may be some limitations on image interpretation,
such as hemorrhages, compared to pre-biopsy images
[29]. However, Park et al. reported that no consensus has
yet been reached regarding the optimal timing of MRI for
acute staging [30], although pre-contrast T1W images
were always included in MRI protocols to improve image
quality. This was because areas of hemorrhage appeared
characteristically hyper-intense on T1W, which reduced
the impact of hemorrhage in the interpretation of these
images. Additionally, only patients with MRI images
where there was no image interpretation restriction, based
on PI-RADS grade determined by the experienced urora-
diologist, were selected. Patients with any limitations of
interpretation owing to pre-biopsy images were excluded.
Despite these limitations, our study remains informative
for clinicians who treat patients with iPCa on mpMRI.
As for the strengths of our study, to the best of our
knowledge, this is the first investigation of long-term onco-
logic outcomes and prognostic factors in patients with iPCa
based on PI-RADS who underwent RP. Furthermore, we
investigated the long-term follow up oncologic outcomes of
iPCa with an established protocol. No patients were treated
with adjuvant androgen deprivation therapy or radiotherapy
until BCR. This allowed us to observe the natural history of
BCR after RP. Based on this, our study provides criteria for
predicting adverse oncologic outcomes of patients with
iPCa without further preoperative examination. Clinical in-
formation, especially increased PSA, may help to determine
the direction of treatment for patients with iPCa beyond
the use of MRI data alone. This may be a criterion for clini-
cians to consider a systematic prostate biopsy for iPCa or
to administer aggressive treatment in patients with PCa that
has already been diagnosed.
Our study used mpMRI as a preoperative image mo-
dality. Recently, modalities, such as prostate-specific
membrane antigen ligand positron emission tomog-
raphy, have been used for the diagnosis and treatment of
prostate cancer, recently. We believe that the develop-
ment of these modalities may be a way to overcome
mpMRI limitations observed in our study [31, 32].
Conclusions
Our results demonstrate that iPCa on mpMRI can have
AP, and its oncologic prognosis is not always good. There-
fore, invisible tumors on mpMRI do not appear to predict
insignificant clinical implications. Among such tumors,
there is a clinically significant cancer incidence. In
addition, our results showed that PSA is the most clinic-
ally reliable predictor of pathologic outcome and progno-
sis of iPCa. Specifically, PSA above 6.2 ng/ml was
significant in iPCa in relation to its oncologic prognosis.
In the present results, we suggest that aggressive treat-
ment such as RP should be performed in patients with in-
visible cancer on mpMRI if it is clinically necessary, such
as in patients with elevated PSA > 6.2 ng/ml. Finally, when
prostate biopsy is clinically needed, such as in cases with
PSA elevation, a negative mpMRI finding should not be a
prerequisite for excluding systematic biopsy.
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